AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3124602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise increase in daily dosage (1 to 4 g/kg) at a steady rate over 16 hours, followed by a rest period of eight hours
Number of subjects: 45
Study 3124602 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dosage (4 g/kg) at a steady rate over 24 hours
Number of subjects: 45
Study 30956160 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-implant overdentures (IODs)
Number of subjects: 22
Study 30956160 — intervention group
Group type: COMPARATOR
Intervention: New complete dentures (CDs)
Number of subjects: 22
Study 27739230 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC-520 Injection (0.01-4.0 mg/kg)
Number of subjects: 54
Study 27739230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 26220024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine users
Number of subjects: 83
Study 26220024 — intervention group
Group type: COMPARATOR
Intervention: Non-drug-using healthy males
Number of subjects: 83
Study 22903391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg
Number of subjects: 149
Study 22903391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg
Number of subjects: 149
Study 22903391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 21764706 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 µg daily subcutaneous injection for 7 days)
Number of subjects: 50
Study 21764706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication before surgery)
Number of subjects: 50
Study 18385744 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg day(‐1))
Number of subjects: 25
Study 18385744 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 25
Study 18385744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients (without treatment)
Number of subjects: 25
Study 16495011 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS of M1
Number of subjects: 20
Study 16495011 — intervention group
Group type: COMPARATOR
Intervention: rTMS of S1, preM, and SMA
Number of subjects: 20
Study 16495011 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 14629937 — intervention group
Group type: EXPERIMENTAL
Intervention: Midvastus approach
Number of subjects: 30
Study 14629937 — intervention group
Group type: COMPARATOR
Intervention: Medial para‐patellar approach
Number of subjects: 30
Study 11073734 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% tea tree oil nasal ointment and 5% tea tree oil body wash
Number of subjects: 0
Study 11073734 — intervention group
Group type: COMPARATOR
Intervention: 2% mupirocin nasal ointment and triclosan body wash
Number of subjects: 0
Study 8762212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined slow-release verapamil (180 mg daily) and trandolapril (1.6 mg daily)
Number of subjects: 24
Study 8762212 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (71 mg daily) and chlortalidone (18 mg daily)
Number of subjects: 24
Study 8762212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1315294 — intervention group
Group type: EXPERIMENTAL
Intervention: Six additional cycles of chemotherapy (lomustine, cyclophosphamide, doxorubicin, etoposide)
Number of subjects: 79
Study 1315294 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment until relapse (control group)
Number of subjects: 79
Study 6384489 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive, problem-solving group intervention
Number of subjects: 0
Study 6384489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30718038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 238
Study 30718038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 29544956 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 39
Study 29544956 — intervention group
Group type: COMPARATOR
Intervention: PP-EES
Number of subjects: 39
Study 27452639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement of n-3 PUFA (720mg 20:5n3 + 480mg 22:6n3/d)
Number of subjects: 40
Study 27452639 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.8g oleic acid/d)
Number of subjects: 40
Study 24571729 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (details not specified)
Number of subjects: 76
Study 22321325 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational group received comprehensive health education including dietary guidance and psychological support.
Number of subjects: 125
Study 22321325 — intervention group
Group type: COMPARATOR
Intervention: Control group received traditional health education with routine preoperative education.
Number of subjects: 125
Study 19421067 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia‐based tutorials
Number of subjects: 0
Study 19421067 — intervention group
Group type: COMPARATOR
Intervention: Traditional, lecture‐based models
Number of subjects: 0
Study 16882901 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar fascia-stretching protocol
Number of subjects: 82
Study 16882901 — intervention group
Group type: COMPARATOR
Intervention: Achilles tendon-stretching protocol
Number of subjects: 82
Study 15598475 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 10 microg BID via multidose DPI
Number of subjects: 239
Study 15598475 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 180 microg QID via pMDI
Number of subjects: 239
Study 15598475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 11398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal Replacement Therapy (HRT)
Number of subjects: 112
Study 9252601 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of postoperative immobilization
Number of subjects: 42
Study 9252601 — intervention group
Group type: COMPARATOR
Intervention: 3 weeks of postoperative immobilization
Number of subjects: 42
Study 8334946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (500 mg/m2 initially, increased by 250 mg/m2 to a maximum of 1,000 mg/m2, administered in cycles every 4 weeks)
Number of subjects: 21
Study 8334946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (group A treated for 3 months)
Number of subjects: 21
Study 8334946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (group B treated for over 12 months)
Number of subjects: 21
Study 8334946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (overall treatment)
Number of subjects: 21
Study 3819345 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrics clinic with an interdisciplinary team
Number of subjects: 26
Study 3819345 — intervention group
Group type: COMPARATOR
Intervention: General medical clinic without an interdisciplinary team
Number of subjects: 26
Study 768512 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial impregnated dressings (nitrofurazone)
Number of subjects: 0
Study 768512 — intervention group
Group type: COMPARATOR
Intervention: Non-antibacterial impregnated dressings
Number of subjects: 0
Study 768512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurazone dressings
Number of subjects: 0
Study 768512 — intervention group
Group type: COMPARATOR
Intervention: Both dressing types
Number of subjects: 0
Study 31818839 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention including daily weighing, tracking weight using an app, planning daily actions for weight loss, and weekly reflection on action plans.
Number of subjects: 100
Study 31818839 — intervention group
Group type: COMPARATOR
Intervention: Daily self-weighing without further support (control group).
Number of subjects: 100
Study 31818839 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention.
Number of subjects: 100
Study 31818839 — intervention group
Group type: COMPARATOR
Intervention: Daily self-weighing (control group).
Number of subjects: 100
Study 27732431 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC) at lower inflation pressure
Number of subjects: 32
Study 27732431 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC) at higher inflation pressure
Number of subjects: 32
Study 27732431 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study 27732431 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote limb ischemic conditioning (RLIC)
Number of subjects: 32
Study 25881274 — intervention group
Group type: EXPERIMENTAL
Intervention: Trialist app intervention group
Number of subjects: 244
Study 25881274 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 244
Study 23892493 — intervention group
Group type: EXPERIMENTAL
Intervention: DAILIES TOTAL1 (DT1)
Number of subjects: 104
Study 23892493 — intervention group
Group type: COMPARATOR
Intervention: C1D (Clariti 1day)
Number of subjects: 104
Study 23892493 — intervention group
Group type: COMPARATOR
Intervention: AVTE (1-DAY ACUVUE TRUEYE)
Number of subjects: 104
Study 23892493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative Comfort (CC) for DT1
Number of subjects: 104
Study 23892493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative Comfort (CC) for asymptomatic group
Number of subjects: 104
Study 21278424 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 328
Study 21278424 — intervention group
Group type: EXPERIMENTAL
Intervention: C reactive protein (CRP)
Number of subjects: 328
Study 21278424 — intervention group
Group type: EXPERIMENTAL
Intervention: Total white blood cells count (WBC)
Number of subjects: 328
Study 21278424 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute neutrophil count (ANC)
Number of subjects: 328
Study 21278424 — intervention group
Group type: COMPARATOR
Intervention: Clinical evaluation
Number of subjects: 328
Study 19471293 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 57
Study 19471293 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 57
Study 17902334 — intervention group
Group type: COMPARATOR
Intervention: Full-time Essix retainer wear
Number of subjects: 60
Study 17902334 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time Essix retainer wear
Number of subjects: 60
Study 17902334 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Full-time and Part-time)
Number of subjects: 60
Study 15243483 — intervention group
Group type: EXPERIMENTAL
Intervention: Wand Plus injection system
Number of subjects: 40
Study 15243483 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 40
Study 15243483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study 11692587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg orally daily starting on postoperative day 1 for 14 days)
Number of subjects: 80
Study 11692587 — intervention group
Group type: COMPARATOR
Intervention: Control (no Sotalol)
Number of subjects: 80
Study 9130032 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (METH, 125 mg i.v. infusion followed by 40 mg/d orally for 4 days)
Number of subjects: 20
Study 9130032 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (METH, 40 mg/d orally for 4 days)
Number of subjects: 20
Study 9130032 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 20
Study 7967919 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion diet
Number of subjects: 0
Study 7967919 — intervention group
Group type: COMPARATOR
Intervention: Unrefined carbohydrate, fiber-rich diet
Number of subjects: 0
Study 3310197 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg) administered by intravenous injection
Number of subjects: 0
Study 3310197 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered by intravenous injection
Number of subjects: 0
Study 3310197 — intervention group
Group type: COMPARATOR
Intervention: Comparison of omeprazole and placebo
Number of subjects: 0
Study 31690970 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-set logatome test
Number of subjects: 25
Study 29522236 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine intake forms with SOGI questions
Number of subjects: 491
Study 29522236 — intervention group
Group type: COMPARATOR
Intervention: Routine intake forms (control)
Number of subjects: 491
Study 27606710 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized training for therapists (including theoretical, technical, and supervised practical training)
Number of subjects: 79
Study 25663281 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training program (8 weeks, 3 days/week, 70% of 6 RM)
Number of subjects: 44
Study 25663281 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 44
Study 23083533 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective fatigue (increased fatigue class)
Number of subjects: 2781
Study 23083533 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective fatigue (persistent fatigue class)
Number of subjects: 2781
Study 23083533 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective fatigue (decreased fatigue class)
Number of subjects: 2781
Study 23083533 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective fatigue (persistent energy class)
Number of subjects: 2781
Study 23083533 — intervention group
Group type: COMPARATOR
Intervention: Cognitive function and everyday functioning
Number of subjects: 2781
Study 23083533 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline rates of subjective fatigue
Number of subjects: 2781
Study 20810853 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐fraction radiation therapy of 700 cGy immediately postoperatively (within seventy‐two hours)
Number of subjects: 45
Study 20810853 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 45
Study 20810853 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐fraction radiation therapy
Number of subjects: 45
Study 19023429 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% cellulose sulfate vaginal gel
Number of subjects: 1644
Study 19023429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1644
Study 16442388 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting without balloon predilatation
Number of subjects: 1000
Study 16442388 — intervention group
Group type: COMPARATOR
Intervention: Predilatation
Number of subjects: 1000
Study 15261637 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard honesty appeal with varying questionnaire types
Number of subjects: 4140
Study 15261637 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong honesty appeal with varying questionnaire types
Number of subjects: 4140
Study 15261637 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of honesty appeal and questionnaire type
Number of subjects: 4140
Study 15261637 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical question wording across questionnaire types
Number of subjects: 4140
Study 11777234 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge matrix resection (WMR)
Number of subjects: 110
Study 11777234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail matrix phenolization (NMP)
Number of subjects: 110
Study 9265937 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dolasetron
Number of subjects: 514
Study 9265937 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron
Number of subjects: 514
Study 9265937 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 514
Study 9265937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 9265937 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 514
Study 8257492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg rhRlx intravenous (iv)
Number of subjects: 51
Study 8257492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg rhRlx intracervical
Number of subjects: 51
Study 8257492 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg rhRlx intravaginal
Number of subjects: 51
Study 8257492 — intervention group
Group type: COMPARATOR
Intervention: 0 mg rhRlx (placebo) intravaginal
Number of subjects: 51
Study 8257492 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg rhRlx intravaginal
Number of subjects: 51
Study 8257492 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg rhRlx intravaginal
Number of subjects: 51
Study 2876745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide or Propranolol
Number of subjects: 2765
Study 2876745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2765
Study 2876745 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2765
Study 2876745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 2765
Study 2876745 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical variables
Number of subjects: 2765
Study 29313746 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-Restricted (CR) diet
Number of subjects: 90
Study 29313746 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (600 mg daily)
Number of subjects: 90
Study 29313746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27544720 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-menarcheal growth assessment
Number of subjects: 106
Study 27544720 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 106
Study 27544720 — intervention group
Group type: EXPERIMENTAL
Intervention: Height at the moment of menarche
Number of subjects: 106
Study 24122760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 1076
Study 24122760 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy without bevacizumab)
Number of subjects: 1076
Study 22514150 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin 80 mg/day × 2 days before and 40 mg/day × 30 days after PCI
Number of subjects: 1100
Study 22514150 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1100
Study 22514150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive atorvastatin treatment
Number of subjects: 1100
Study 20732527 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified adhesive closure
Number of subjects: 0
Study 20732527 — intervention group
Group type: COMPARATOR
Intervention: Conventional wire closure
Number of subjects: 0
Study 18403272 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cannabis (7%)
Number of subjects: 38
Study 18403272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cannabis (3.5%)
Number of subjects: 38
Study 18403272 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 38
Study 16679760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 16
Study 16679760 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 16
Study 16679760 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 16
Study 16679760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14620385 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote (45, 90, 135, 180, and 225 mg)
Number of subjects: 40
Study 14620385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14620385 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote (up to 225 mg)
Number of subjects: 40
Study 14620385 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood creosote
Number of subjects: 40
Study 10785303 — intervention group
Group type: EXPERIMENTAL
Intervention: Photac‐Fil Quick with various conditioners
Number of subjects: 30
Study 10785303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC with various conditioners
Number of subjects: 30
Study 10785303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX GP with various conditioners
Number of subjects: 30
Study 10785303 — intervention group
Group type: COMPARATOR
Intervention: No conditioner applied to Photac‐Fil Quick
Number of subjects: 30
Study 10785303 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned specimens of Fuji II LC
Number of subjects: 30
Study 10785303 — intervention group
Group type: COMPARATOR
Intervention: Non-conditioned specimens of Fuji IX GP
Number of subjects: 30
Study 8890679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 200
Study 8890679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day
Number of subjects: 200
Study 8890679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 200
Study 8890679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (all doses combined)
Number of subjects: 200
Study 1315662 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive status
Number of subjects: 175
Study 1315662 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed visits
Number of subjects: 175
Study 6367325 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dihydroergotamine
Number of subjects: 114
Study 6367325 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 30825982 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine (KNM‐LS 18354) attributed to Kamoyapithecus
Number of subjects: 0
Study 30825982 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine tip (KNM‐LS 18352) attributed to Kamoyapithecus
Number of subjects: 0
Study 30825982 — intervention group
Group type: EXPERIMENTAL
Intervention: KNM‐LS 1, a smaller lower canine
Number of subjects: 0
Study 30201053 — intervention group
Group type: EXPERIMENTAL
Intervention: NET combined with case management
Number of subjects: 340
Study 30201053 — intervention group
Group type: COMPARATOR
Intervention: Improved treatment as usual (iTAU)
Number of subjects: 340
Study 26729277 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (GBP)
Number of subjects: 28
Study 26729277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 28